Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3348287 | Diagnostic Microbiology and Infectious Disease | 2007 | 11 Pages |
Abstract
The Zyvox® Annual Appraisal of Potency and Spectrum Program has completed its fifth year of monitoring for emerging resistance to linezolid and other Gram-positive active agents on the continents of Europe, Asia, Australia, and Latin America. In 2006, 4216 Gram-positive isolates from 16 nations were submitted for analysis from 6 organism groups including Staphylococcus aureus (54.0%), coagulase-negative staphylococci (CoNS) (14.6%), enterococci (10.0%), Streptococcus pneumoniae (9.4%), viridans group streptococci (5.0%), and β-hemolytic streptococci (7.0%). Linezolid retained potent activity against S. aureus (MIC50 and MIC90, 2 μg/mL; 39.8% methicillin resistant) and CoNS (MIC50 and MIC90, 1 μg/mL; 74.3% methicillin resistant). Despite endemicity of vancomycin-resistant enterococci (up to 30.0%) in several nations, linezolid inhibited >99% of strains at â¤2 μg/mL (modal MIC, 1 μg/mL). Among streptococci, all linezolid MIC values were â¤2 μg/mL. Rare instances of linezolid-resistance were detected in enterococci (2 isolates, China and Germany) and CoNS (3 isolates, Italy and Brazil); 2 CoNS and 1 Enterococcus faecium had documented G2576T mutations. Overall, linezolid remained active against 99.88% of tested strains from this global collection.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Applied Microbiology and Biotechnology
Authors
Ronald N. Jones, Thomas R. Fritsche, Helio S. Sader, James E. Ross,